NPI: 1235198193 · SALEM, MA 01970 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/20/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 03/20/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 24,897 | $506K |
| 2019 | 26,698 | $570K |
| 2020 | 22,418 | $551K |
| 2021 | 15,956 | $559K |
| 2022 | 19,445 | $488K |
| 2023 | 13,062 | $470K |
| 2024 | 9,013 | $424K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 58,947 | 4,543 | $3.57M |
| 82728 | 1,825 | 1,751 | $0.00 | |
| A4657 | Syringe, with or without needle, each | 3,099 | 2,569 | $0.00 |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 35,911 | 1,822 | $0.00 |
| J1270 | Injection, doxercalciferol, 1 mcg | 13,997 | 1,203 | $0.00 |
| 83550 | 1,323 | 1,276 | $0.00 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 869 | 705 | $0.00 |
| J0604 | Cinacalcet, oral, 1 mg, (for esrd on dialysis) | 44 | 24 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 73 | 72 | $0.00 |
| 85048 | 2,167 | 2,070 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 5,892 | 1,591 | $0.00 |
| 83970 | 1,896 | 1,822 | $0.00 | |
| 85041 | 2,171 | 2,073 | $0.00 | |
| 82108 | 496 | 492 | $0.00 | |
| 83540 | 1,931 | 1,851 | $0.00 | |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 806 | 455 | $0.00 |
| 90662 | 42 | 41 | $0.00 |